Differential effects of cyclodextrins and derivatives on the biological behavior of the myocardial perfusion imaging agent 99mTcN-NOET

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 61, Issue 1-2, 2005, Pages 40-49

  Riou, Laurent ^a   Ghezzi, Catherine ^a   Wouessidjewe, Denis ^b   Law, Ho ^b   Mathieu, Jean Paul ^a   Defaye, Jacques ^b   Bontron, René ^a   Pasqualini, Roberto ^c   Fagret, Daniel ^a  

^a INSERM   (France)

^b Laboratoire de Pharmacochimie   (France)

^c CIS Bio International   (France)

Author keywords

99mTcN NOET; Anesthetized dogs; Cardiomyocytes; Cyclodextrin derivatives; Cyclodextrins; Isolated rat hearts

Indexed keywords

(2 HYDROXYPROPYL) BETA CYCLODEXTRIN; 6 AMINO 6 DEOXY BETA CYCLODEXTRIN; 6 DEOXY 6 (METHYLTHIOUREIDO) BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BIS(N ETHOXY N ETHYLDITHIOCARBAMATO)NITRIDO TC 99M; CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; GAMMA CYCLODEXTRIN; HEPTAKIS(2,3,6 O TRIMETHYL) BETA CYCLODEXTRIN; HEPTAKIS(2,6 O DIMETHYL) BETA CYCLODEXTRIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG SOLUBILITY; HEART MUSCLE CELL; HEART MUSCLE PERFUSION; IMAGING SYSTEM; IN VITRO STUDY; ISOLATED HEART; LIPOPHILICITY; NEWBORN; NONHUMAN; RADIOACTIVITY; RAT; REGRESSION ANALYSIS; SOLUBILIZATION;

EID: 23244436448     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2005.03.005     Document Type: Article

References (32)

1. K. Uekama, F. Hirayama, and T. Irie Cyclodextrin drug carrier systems Chem. Rev. 98 1998 2045 2076
2. Y. Ohtani, T. Irie, K. Uekama, K. Fukunaga, and J. Pitha Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes Eur. J. Biochem. 186 1989 17 22
3. F. Fauvelle, J.C. Debouzy, S. Crouzy, M. Göschl, and Y. Chapron Mechanism of alpha-cyclodextrin-induced hemolysis. The two-step extraction of phosphatidylinositol from the membrane J. Pharm. Sci. 86 1997 935 943
4. M. Bost, V. Lainé, F. Pilard, A. Gadelle, J. Defaye, and B. Perly The hemolytic properties of chemically modified cyclodextrins J. Incl. Phenom. 29 1997 57 63
5. J. Szejtli Medicinal applications of cyclodextrins Med. Red. Rev. 14 1994 353 386
6. T. Loftsson, and M.E. Brewster Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization J. Pharm. Sci. 85 1996 1017 1025
7. R. Pasqualini, A. Duatti, E. Bellande, V. Comazzi, V. Brucato, D. Hoffschir, D. Fagret, and M. Comet Bis(dithiocarbamato)nitrido technetium-99m radiopharmaceuticals: a class of neutral myocardial imaging agents J. Nucl. Med. 35 1994 334 341
8. C. Ghezzi, D. Fagret, C.C. Arvieux, J.P. Mathieu, R. Bontron, R. Pasqualini, J. de Leiris, and M. Comet Myocardial kinetics of TcN-NOET: a neutral lipophilic complex tracer of regional myocardial blood flow J. Nucl. Med. 36 1995 1069 1077
9. G. Vanzetto, D. Fagret, R. Pasqualini, J.P. Mathieu, F. Chossat, and J. Machecourt Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99m-TcN-NOET in healthy volunteers J. Nucl. Med. 41 2000 141 148
10. D. Fagret, P.Y. Marie, and F. Brunotte Myocardial perfusion imaging with technetium-99m-TcN-NOET: comparison with Thallium 201 and coronary angiography J. Nucl. Med. 36 1995 936 943
11. L. Riou, C. Ghezzi, O. Mouton, J.P. Mathieu, R. Pasqualini, M. Comet, and D. Fagret Cellular uptake mechanisms of TcN-NOET in cardiomyocytes from newborn rats: calcium channel interaction Circulation 98 1998 2591 2597
12. R.C. Petter, J.S. Salec, C.T. Sikorski, G. Kumaravel, and F.T. Lin Comparative binding by aggregated mono-6-(alkylamino)-β-cyclodextrins J. Am. Chem. Soc. 112 1990 3860 3868
13. C. Ortiz-Mellet, J.M. Benito, J.M. Garcia Fernandez, H. Law, K. Chmerski, J. Defaye, M.L. O'Sullivan, and H.N. Caro Cyclodextrin-scaffolded glycocluster Chem. Eur. J. 4 1998 2523 2531
14. I. Harary, and B. Farley In vitro studies on single beating rat heart cells: I. Growth and organization Exp. Cell Res. 29 1963 451 465
15. B. Blondel, I. Roijen, and J.P. Cheneval Heart cells in culture: a simple method for increasing the proportion of myoblastes Experientia 27 1970 356 358
16. O.H. Lowry, N.J. Rosebrough, A. Lewis Farr, and R.J. Randall Protein measurement with the Folin phenol reagent J. Biol. Chem. 193 1951 265 275
17. O. Langendorff Untersuchungen am überlebenden Saügetiertherzen Pflügers Arch 61 1895 291 332
18. L. Riou, C. Ghezzi, R. Pasqualini, and D. Fagret Influence of calcium channel inhibitors on the myocardial uptake and retention of technetium 99m-N-NOET, a new myocardial perfusion imaging agent: a study on isolated perfused rat hearts J. Nucl. Cardiol. 7 2000 365 372
19. T. Irie, and K. Uekama Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation J. Pharm. Sci. 2 1997 147 162
20. T. Loftsson, and M. Masson Cyclodextrin in topical drug formulation: theory and practice Int. J. Pharm. 225 2001 15 30
21. G. Piel, G. Dive, B. Evrard, T. Van Hees, S.H. de Hassonville, and L. Delattre Molecular modeling study of beta-and gamma-cyclodextrin complexes with miconazole Eur. J. Pharm. Sci. 13 2001 271 279
22. F. Leroy-Lechat, D. Wouessidjewe, J-P. Andreux, F. Puisieux, and D. Duchêne Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivatives Int. J. Pharm. 101 1994 97 103
23. L. Hovgaard, and H. Brondsted Drug delivery studies in Caco-2 monolayers. IV. Absorption enhancer effects of cyclodextrins Pharm. Res. 12 1995 1328 1332
24. V. Lemesle-Lamache, M. Taverna, D. Wouessidjewe, D. Duchêne, and D. Ferrier Determination of binding constant of salbutamol to unmodified and ethylated cyclodextrins by affinity capillary electrophoresis J. Chromatogr. A 735 1996 321 331
25. M.M. Echezarreta-Lopez, I. Perdomo-Lopez, E. Estrada, J.L. Vila-Jato, and J.J. Torres-Labandeira Utility of nuclear magnetic resonance spectroscopy to characterize the structure of dexamethasone sodium phosphate inclusion complexes with cyclodextrins in solution and to analyze potential competitive effects J. Pharm. Sci. 91 2002 1536 1547
26. E. Redenti, C. Pietra, A. Gerloczy, and L. Szente Cyclodextrins in oligonucleotide delivery Adv. Drug Deliv. Rev. 53 2001 235 244
27. L. Uccelli, M. Giganti, A. Duatti, C. Bolzati, R. Pasqualini, C. Cittanti, P. Colamussi, and A. Piffanelli Subcellular distribution of technetium-99m-TcN-NOET in rat myocardium J. Nucl. Med. 36 1995 2075 2079
28. F. Demaimay, L. Dazord, A. Roucoux, N. Noiret, H. Patin, and A. Moisan Rhenium-188 and technetium-99m nitridobis(N-ethoxy-N-ethyldithiocarbamate) leukocyte labelling radiopharmaceuticals: [188ReN(NOET)2] and [99mTcN(NOET)2] NOET=Et(EtO)NCS2: their in vitro localization and chemical behaviour Nucl. Med. Biol. 24 1997 701 705
29. Q. Zhao, J. Temsamani, and S. Agrawal Use of cyclodextrin and its derivatives as carriers for oligonucleotide delivery Antisense Res. Dev. 5 1995 185 192
30. 99mTcN-NOET with blood elements: a potential mechanism of myocardial redistribution J. Nucl. Med. 38 1997 138 143
31. 99mTcN-NOET J. Nucl. Med. 44 2003 1092 1098
32. Z. Zuo, Y.K. Tam, J. Diakur, and L.I. Wiebe Hydroxypropyl-β- cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat J. Pharm. Pharm. Sci. 5 2002 292 298